Option chain shows key data for Evofem Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Evofem Biosciences.

Evofem Biosciences (OTC:EVFM) Stock, Option Chain

Evofem Biosciences

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

News

Penny Stocks

Health Care

Movers

General

ADTX

EVFM

Aditxt Inc (NASDAQ: ADTX) has agreed to acquire Evofem Biosciences Inc (OTC: EVFM) in consideration of the issuance of a combination of common stock and preferred stock and the assumption of certain senior i

Why Is Life Sciences-Focused Aditxt Stock Trading Higher Today?

OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes

Small Cap

Markets

AAUKF

ASMIY

ATLX

BDRBF

CLNV

CRTD

CWGL

CYDY

DANOY

ETHE

FISOF

GBTC

GPOX

JBSAY

Fidelity NASDAQmposite Index Fund ETF-Tracking NASDAQmposite Index

ONEQ

OTCM

RHHBY

VIHDD

ZURVY

The SPDR S&amp;P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022.

OTC Market Group&#39;s Most Active List In November: A Dive Into The Names Experiencing Volume Changes

Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?

AGRX

DARE

From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products.

Can This Company&#39;s Birth Control Patch Disrupt The Contraceptive Market?

EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc.

Evofem Biosciences Inc

Earnings

Press Releases

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store

Comments

Evofem Biosciences

Evofem Biosciences (EVFM) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell